Key Investor Signals
Founders bring two prior biotech company exits
Olle Isaksson co-founded Tercica, acquired by Ipsen at about $663M. Thomas Hedner founded DuoCort, acquired by ViroPharma for $33.6M upfront plus up to $131M in milestones.
Founder co-authored Phase 3 oral-mucositis trial
Mats Jontell co-authored a randomized, blinded, multicentre Phase 3 trial in 172 patients evaluating oral-mucositis prevention during high-dose chemotherapy.
Founders bring granted oral-mucosa patent experience
All four founders are named inventors on a Mucocort patent family covering inflammatory conditions of mucous membranes, with European and US patents granted.
Other Positive Signals
- Joined Umeå Biotech Incubator for biotech development support, facilities and financing.
- Spun out of Mucocort, extending the same scientific team's oral-mucosa research into oncology.
- Preparing a Phase 1a clinical trial application for submission to the Swedish Medical Products Agency.
Team
Jean Lycke
Founder & Project Lead
- Brings more than 35 years of pharmaceutical and consulting experience across commercial and development roles.
- Spent more than five years developing Mucocort's oral-mucosa programme, giving him direct product-development experience.
- Named inventor on Mucocort’s European and US patent family covering treatment of inflammatory conditions of mucous membranes and skin.
Mats Jontell
Founder & Professor Emeritus of Oral Medicine and Pathology
- Professor Emeritus of Oral Medicine and Pathology at the University of Gothenburg, with direct expertise in oral mucosal disease.
- Co-authored a randomized, blinded Phase 3 trial in 172 patients evaluating oral-mucositis prevention during high-dose chemotherapy.
- Published human and preclinical research on oral-mucosal blood flow and chemotherapy-related mucositis, directly matching MucoShield’s target biology.
Olle Isaksson
Founder & Professor Emeritus of Endocrinology
- Co-founded Tercica, helped secure its first seed financing and saw the endocrinology company later acquired by Ipsen at an approximately $663M valuation.
- Professor of Endocrinology from 1989 and later Chairman and Chief Physician of Internal Medicine at Sahlgrenska University Hospital.
- Named inventor on Mucocort’s European and US patent family for treatments targeting inflammatory conditions of mucous membranes and skin.
Thomas Hedner
Founder & Professor Emeritus of Clinical Pharmacology
- Professor Emeritus of Clinical Pharmacology at the University of Gothenburg, after serving as professor and senior physician at Sahlgrenska.
- Founded DuoCort, later acquired by ViroPharma for $33.6M upfront plus up to $131M in milestone payments.
- Author of more than 400 scientific publications and served as editor-in-chief of the journal Blood Pressure for more than 20 years.
Product
MucoShield is developing locally applied treatments for oral complications of chemotherapy. Its lead programme is designed for administration before chemotherapy, with a separate early programme focused on xerostomia.
Local pre-chemotherapy treatment
The lead candidate is intended to be applied directly in the mouth before chemotherapy, concentrating treatment at the oral mucosa to provide targeted local protection during administration.
Limiting oral tissue exposure to chemotherapy
The programme is designed to temporarily alter blood flow in the oral mucosa, with the aim of limiting tissue exposure to cytotoxic chemotherapy during drug administration.
Gel and spray formulations
MucoShield is developing a gel that forms a protective layer on the oral mucosa and a spray designed for broad local application across the mouth. Both are intended for use around chemotherapy administration.
Market Overview
Oral mucositis can cause painful mouth ulcers, infection risk and difficulty eating or drinking during cancer treatment. Severe cases can lead to chemotherapy dose reductions, delays or interruptions, making prevention relevant to supportive care and maintaining continuity of oncology treatment.
MucoShield is entering an established supportive-oncology category with preventive approaches that include cryotherapy, barrier products and growth-factor therapies. The opportunity is concentrated in regimens with substantial oral toxicity, where a simple locally administered option could fit into existing treatment workflows.
Pooled prevalence across 24 cross-sectional studies in a 2026 systematic review and meta-analysis.
Estimated global market for oral-mucositis treatments, including barriers, topical analgesics and cryotherapy.
Pooled dry-mouth prevalence in the same 2026 meta-analysis of patients receiving chemotherapy.
Reported oral-mucositis incidence among patients receiving high-dose chemotherapy.
Comparable Outcomes
RxKinetix
RxKinetix developed EN3285, a topical treatment for preventing oral mucositis in cancer patients receiving radiation or chemotherapy. The programme was in Phase II when Endo acquired the company. Endo acquired all outstanding RxKinetix stock in 2006 for $20.5M, with up to $95M in additional payments tied to clinical and regulatory milestones.
Onxeo / Validive
Validive is a clonidine mucoadhesive buccal tablet developed for severe oral mucositis in patients receiving chemoradiation for head and neck cancer. Monopar licensed Validive worldwide from Onxeo in 2017 for a $1M fee, up to $108M in milestones and escalating royalties on future sales.
Interested in More Startups Like MucoShield?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.